{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:12:46Z","timestamp":1789906366136,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP17fk0210106"],"award-info":[{"award-number":["JP17fk0210106"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP18fk0210022"],"award-info":[{"award-number":["JP18fk0210022"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jhep.2018.09.029","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T04:03:59Z","timestamp":1539662639000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy"],"prefix":"10.1016","volume":"70","author":[{"given":"Mizuki","family":"Nishibatake Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-892X","authenticated-orcid":false,"given":"Tatsuya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-2517","authenticated-orcid":false,"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijiro","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-9664","authenticated-orcid":false,"given":"Masaya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Enooku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.09.029_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2018.09.029_b0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7326\/0003-4819-116-2-97","article-title":"Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study","volume":"116","author":"Simonetti","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2018.09.029_b0015","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.09.029_b0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","article-title":"Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus","volume":"138","author":"Shiratori","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2018.09.029_b0025","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.09.029_b0030","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jhep.2009.12.041","article-title":"Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach","volume":"52","author":"Shen","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0035","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1111\/hepr.12468","article-title":"Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma","volume":"45","author":"Minami","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2018.09.029_b0040","doi-asserted-by":"crossref","unstructured":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016;65:734\u2013740.","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"10.1016\/j.jhep.2018.09.029_b0045","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.09.029_b0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0060","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","article-title":"The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma","volume":"65","author":"Minami","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2018.09.029_b0070","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510300411","article-title":"Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy","volume":"30","author":"Torzilli","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.09.029_b0075","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2016.05.034","article-title":"Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment","volume":"65","author":"Torres","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0080","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jhep.2016.07.029","article-title":"Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?","volume":"62","author":"Zeng","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0085","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","article-title":"Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma","volume":"62","author":"Ikeda","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2018.09.029_b0090","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0095","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.09.029_b0105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.09.029_b0110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2016.08.016","article-title":"Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?","volume":"66","author":"Zavaglia","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOG.0000000000000431","article-title":"Direct-acting antiviral treatment for patients with hepatocellular carcinoma","volume":"34","author":"Kushner","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2018.09.029_b0120","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.21408","article-title":"Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers","volume":"44","author":"Tateishi","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.09.029_b0125","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1056\/NEJM199306243282502","article-title":"Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein","volume":"328","author":"Sato","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.09.029_b0130","first-page":"5419","article-title":"A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma","volume":"53","author":"Taketa","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2018.09.029_b0135","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1440-1746.2006.04732.x","article-title":"Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment","volume":"22","author":"Yamashiki","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.09.029_b0140","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/liv.13357","article-title":"A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma","volume":"37","author":"Cabibbo","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.09.029_b0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818324541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818324541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:04:54Z","timestamp":1605240294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818324541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0168827818324541"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.09.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}